{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:31:48Z","timestamp":1789648308371,"version":"4.0.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Lind Pharma, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm Regener"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      ONO-1301 is a novel long-lasting prostaglandin (PG) I\n                      <jats:sub>2<\/jats:sub>\n                      mimetic with inhibitory activity on thromboxane (TX) A\n                      <jats:sub>2<\/jats:sub>\n                      synthase. This drug can also induce endogenous prostaglandin (PG)I2 and PGE2 levels. Furthermore, ONO-1301 acts as a cytokine inducer and can initiate tissue repair in a variety of diseases, such as pulmonary hypertension, pulmonary fibrosis, cardiac infarction, and obstructive nephropathy. In this study, our aim was to evaluate the effect of ONO-1301 on liver inflammation and fibrosis in a mouse model of non-alcoholic steatohepatitis (NASH).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The therapeutic effects of ONO-1301 against liver damage, fibrosis, and occurrence of liver tumors were evaluated using melanocortin 4 receptor-deficient (\n                      <jats:italic>Mc4r<\/jats:italic>\n                      -KO) NASH model mice. The effects of ONO-1301 against macrophages, hepatic stellate cells, and endothelial cells were also evaluated in vitro.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      ONO-1301 ameliorated liver damage and fibrosis progression, was effective regardless of NASH status, and suppressed the occurrence of liver tumors in\n                      <jats:italic>Mc4r<\/jats:italic>\n                      -KO NASH model mice. In the in vitro study, ONO-1301 suppressed LPS-induced inflammatory responses in cultured macrophages, suppressed hepatic stellate cell (HSC) activation, upregulated vascular endothelial growth factor (VEGF) expression in HSCs, and upregulated hepatocyte growth factor (HGF) and VEGF expression in endothelial cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of our study highlight the potential of ONO-1301 to reverse the progression and prevent the occurrence of liver tumors in NASH using in vivo and in vitro models. ONO-1301 is a multidirectional drug that can play a key role in various pathways and can be further analyzed for use as a new drug candidate against NASH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41232-021-00191-6","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T22:04:54Z","timestamp":1643666694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A novel prostaglandin I2 agonist, ONO-1301, attenuates liver inflammation and suppresses fibrosis in non-alcoholic steatohepatitis model mice"],"prefix":"10.1186","volume":"42","author":[{"given":"Satoko","family":"Motegi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsunori","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Natsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Nojiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suguru","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosiki","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Sawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Terai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,1]]},"reference":[{"issue":"1","key":"191_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology."},{"issue":"3","key":"191_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00535-021-01759-2","volume":"56","author":"S Terai","year":"2021","unstructured":"Terai S, Buchanan-Hughes A, Ng A, Lee IH, Hasegawa K. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database. J Gastroenterol. 2021;56(3):274\u201384. https:\/\/doi.org\/10.1007\/s00535-021-01759-2.","journal-title":"J Gastroenterol."},{"issue":"5","key":"191_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00535-012-0533-z","volume":"47","author":"Y Eguchi","year":"2012","unstructured":"Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47(5):586\u201395. https:\/\/doi.org\/10.1007\/s00535-012-0533-z.","journal-title":"J Gastroenterol."},{"issue":"6","key":"191_CR4","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","volume":"18","author":"R Vuppalanchi","year":"2021","unstructured":"Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2021;18(6):373\u201392. https:\/\/doi.org\/10.1038\/s41575-020-00408-y.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"191_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.reth.2020.03.012","volume":"14","author":"T Watanabe","year":"2020","unstructured":"Watanabe T, Tsuchiya A, Takeuchi S, Nojiri S, Yoshida T, Ogawa M, et al. Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles. Regen Ther. 2020;14:252\u201361. https:\/\/doi.org\/10.1016\/j.reth.2020.03.012.","journal-title":"Regen Ther."},{"issue":"4","key":"191_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbrc.2020.07.099","volume":"530","author":"T Yoshida","year":"2020","unstructured":"Yoshida T, Tsuchiya A, Kumagai M, Takeuchi S, Nojiri S, Watanabe T, et al. Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH. Biochem Biophys Res Commun. 2020;530(4):665\u201372. https:\/\/doi.org\/10.1016\/j.bbrc.2020.07.099.","journal-title":"Biochem Biophys Res Commun."},{"key":"191_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bbrc.2021.05.097","volume":"566","author":"T Sato","year":"2021","unstructured":"Sato T, Tsuchiya A, Owaki T, Kumagai M, Motegi S, Iwasawa T, et al. Severe steatosis and mild colitis are important for the early occurrence of hepatocellular carcinoma. Biochem Biophys Res Commun. 2021;566:36\u201344. https:\/\/doi.org\/10.1016\/j.bbrc.2021.05.097.","journal-title":"Biochem Biophys Res Commun."},{"issue":"5","key":"191_CR8","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1016\/j.ajpath.2011.07.014","volume":"179","author":"M Itoh","year":"2011","unstructured":"Itoh M, Suganami T, Nakagawa N, Tanaka M, Yamamoto Y, Kamei Y, et al. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis. Am J Pathol. 2011;179(5):2454\u201363. https:\/\/doi.org\/10.1016\/j.ajpath.2011.07.014.","journal-title":"Am J Pathol."},{"issue":"12","key":"191_CR9","doi-asserted-by":"publisher","first-page":"e82163","DOI":"10.1371\/journal.pone.0082163","volume":"8","author":"M Itoh","year":"2013","unstructured":"Itoh M, Kato H, Suganami T, Konuma K, Marumoto Y, Terai S, et al. Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS One. 2013;8(12):e82163. https:\/\/doi.org\/10.1371\/journal.pone.0082163.","journal-title":"PLoS One."},{"issue":"4","key":"191_CR10","doi-asserted-by":"publisher","first-page":"G420","DOI":"10.1152\/ajpgi.00216.2011","volume":"302","author":"Q Xu","year":"2012","unstructured":"Xu Q, Nakayama M, Suzuki Y, Sakai K, Nakamura T, Sakai Y, et al. Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression. Am J Physiol Gastrointest Liver Physiol. 2012;302(4):G420\u20139. https:\/\/doi.org\/10.1152\/ajpgi.00216.2011.","journal-title":"Am J Physiol Gastrointest Liver Physiol."},{"issue":"4","key":"191_CR11","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1254\/jphs.13073FP","volume":"123","author":"T Uchida","year":"2013","unstructured":"Uchida T, Hazekawa M, Yoshida M, Matsumoto K, Sakai Y. Novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling. J Pharmacol Sci. 2013;123(4):392\u2013401. https:\/\/doi.org\/10.1254\/jphs.13073FP.","journal-title":"J Pharmacol Sci."},{"issue":"1","key":"191_CR12","doi-asserted-by":"publisher","first-page":"L59","DOI":"10.1152\/ajplung.00042.2005","volume":"290","author":"S Murakami","year":"2006","unstructured":"Murakami S, Nagaya N, Itoh T, Kataoka M, Iwase T, Horio T, et al. Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2006;290(1):L59\u201365. https:\/\/doi.org\/10.1152\/ajplung.00042.2005.","journal-title":"Am J Physiol Lung Cell Mol Physiol."},{"issue":"12","key":"191_CR13","doi-asserted-by":"publisher","first-page":"F1616","DOI":"10.1152\/ajprenal.00538.2011","volume":"302","author":"T Nasu","year":"2012","unstructured":"Nasu T, Kinomura M, Tanabe K, Yamasaki H, Htay SL, Saito D, et al. Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol Renal Physiol. 2012;302(12):F1616\u201329. https:\/\/doi.org\/10.1152\/ajprenal.00538.2011.","journal-title":"Am J Physiol Renal Physiol."},{"issue":"4","key":"191_CR14","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10741-015-9477-8","volume":"20","author":"S Fukushima","year":"2015","unstructured":"Fukushima S, Miyagawa S, Sakai Y, Sawa Y. A sustained-release drug-delivery system of synthetic prostacyclin agonist, ONO-1301SR: a new reagent to enhance cardiac tissue salvage and\/or regeneration in the damaged heart. Heart Fail Rev. 2015;20(4):401\u201313. https:\/\/doi.org\/10.1007\/s10741-015-9477-8.","journal-title":"Heart Fail Rev."},{"issue":"2","key":"191_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1164\/rccm.200703-349OC","volume":"177","author":"H Obata","year":"2008","unstructured":"Obata H, Sakai Y, Ohnishi S, Takeshita S, Mori H, Kodama M, et al. Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med. 2008;177(2):195\u2013201. https:\/\/doi.org\/10.1164\/rccm.200703-349OC.","journal-title":"Am J Respir Crit Care Med."},{"issue":"6","key":"191_CR16","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/biom11060789","volume":"11","author":"K Li","year":"2021","unstructured":"Li K, Zhao J, Wang M, Niu L, Wang Y, Li Y, et al. The Roles of Various Prostaglandins in Fibrosis: A Review. Biomolecules. 2021;11(6):789. https:\/\/doi.org\/10.3390\/biom11060789.","journal-title":"Biomolecules."},{"key":"191_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtm.2020.09.005","volume":"19","author":"K Masada","year":"2020","unstructured":"Masada K, Miyagawa S, Sakai Y, Harada A, Kanaya T, Sawa Y. Synthetic prostacyclin agonist attenuates pressure-overloaded cardiac fibrosis by inhibiting FMT. Mol Ther Methods Clin Dev. 2020;19:210\u20139. https:\/\/doi.org\/10.1016\/j.omtm.2020.09.005.","journal-title":"Mol Ther Methods Clin Dev."},{"issue":"1","key":"191_CR18","doi-asserted-by":"publisher","first-page":"7292","DOI":"10.1038\/s41598-021-86781-3","volume":"11","author":"T Kanaya","year":"2021","unstructured":"Kanaya T, Miyagawa S, Kawamura T, Sakai Y, Masada K, Nawa N, et al. Innovative therapeutic strategy using prostaglandin I2 agonist (ONO1301) combined with nano drug delivery system for pulmonary arterial hypertension. Sci Rep. 2021;11(1):7292. https:\/\/doi.org\/10.1038\/s41598-021-86781-3.","journal-title":"Sci Rep."},{"issue":"2","key":"191_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1124\/jpet.115.222612","volume":"353","author":"H Kashiwagi","year":"2015","unstructured":"Kashiwagi H, Yuhki K, Kojima F, Kumei S, Takahata O, Sakai Y, et al. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353(2):269\u201378. https:\/\/doi.org\/10.1124\/jpet.115.222612.","journal-title":"J Pharmacol Exp Ther."},{"issue":"1","key":"191_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1002\/hep.21493","volume":"45","author":"H Yin","year":"2007","unstructured":"Yin H, Cheng L, Langenbach R, Ju C. Prostaglandin I(2) and E(2) mediate the protective effects of cyclooxygenase-2 in a mouse model of immune-mediated liver injury. Hepatology. 2007;45(1):159\u201369. https:\/\/doi.org\/10.1002\/hep.21493.","journal-title":"Hepatology."},{"issue":"3","key":"191_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1042\/BJ20081224","volume":"416","author":"R Mayoral","year":"2008","unstructured":"Mayoral R, Molla B, Flores JM, Bosca L, Casado M, Martin-Sanz P. Constitutive expression of cyclo-oxygenase 2 transgene in hepatocytes protects against liver injury. Biochem J. 2008;416(3):337\u201346. https:\/\/doi.org\/10.1042\/BJ20081224.","journal-title":"Biochem J."},{"issue":"3","key":"191_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/sctm.18-0105","volume":"8","author":"Y Watanabe","year":"2019","unstructured":"Watanabe Y, Tsuchiya A, Seino S, Kawata Y, Kojima Y, Ikarashi S, et al. Mesenchymal Stem Cells and Induced Bone Marrow-Derived Macrophages Synergistically Improve Liver Fibrosis in Mice. Stem Cells Transl Med. 2019;8(3):271\u201384. https:\/\/doi.org\/10.1002\/sctm.18-0105.","journal-title":"Stem Cells Transl Med."},{"issue":"1","key":"191_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41536-021-00132-4","volume":"6","author":"S Takeuchi","year":"2021","unstructured":"Takeuchi S, Tsuchiya A, Iwasawa T, Nojiri S, Watanabe T, Ogawa M, et al. Small extracellular vesicles derived from interferon-gamma pre-conditioned mesenchymal stromal cells effectively treat liver fibrosis. NPJ Regen Med. 2021;6(1):19. https:\/\/doi.org\/10.1038\/s41536-021-00132-4.","journal-title":"NPJ Regen Med."},{"issue":"9","key":"191_CR24","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s41580-021-00373-7","volume":"22","author":"L Campana","year":"2021","unstructured":"Campana L, Esser H, Huch M, Forbes S. Liver regeneration and inflammation: from fundamental science to clinical applications. Nat Rev Mol Cell Biol. 2021;22(9):608\u201324. https:\/\/doi.org\/10.1038\/s41580-021-00373-7.","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"2","key":"191_CR25","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00535-016-1258-1","volume":"52","author":"S Terai","year":"2017","unstructured":"Terai S, Tsuchiya A. Status of and candidates for cell therapy in liver cirrhosis: overcoming the \u201cpoint of no return\u201d in advanced liver cirrhosis. J Gastroenterol. 2017;52(2):129\u201340. https:\/\/doi.org\/10.1007\/s00535-016-1258-1.","journal-title":"J Gastroenterol."},{"issue":"1","key":"191_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/j.1749-6632.2009.03698.x","volume":"1155","author":"L Giannitrapani","year":"2009","unstructured":"Giannitrapani L, Ingrao S, Soresi M, Florena AM, La Spada E, Sandonato L, et al. Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study. Ann N Y Acad Sci. 2009;1155(1):293\u20139. https:\/\/doi.org\/10.1111\/j.1749-6632.2009.03698.x.","journal-title":"Ann N Y Acad Sci."},{"issue":"4","key":"191_CR27","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/hep.21108","volume":"43","author":"J Yu","year":"2006","unstructured":"Yu J, Ip E, Dela Pena A, Hou JY, Sesha J, Pera N, et al. COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology. 2006;43(4):826\u201336. https:\/\/doi.org\/10.1002\/hep.21108.","journal-title":"Hepatology."},{"issue":"6","key":"191_CR28","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jhep.2004.08.010","volume":"41","author":"IA Leclercq","year":"2004","unstructured":"Leclercq IA, Farrell GC. Sempoux C, dela Pena A and Horsmans Y. Curcumin inhibits NF-kappaB activation and reduces the severity of experimental steatohepatitis in mice. J Hepatol. 2004;41(6):926\u201334. https:\/\/doi.org\/10.1016\/j.jhep.2004.08.010.","journal-title":"J Hepatol."},{"key":"191_CR29","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jhep.2006.08.025","volume":"46","author":"A dela Pena","year":"2007","unstructured":"dela Pena A, Leclercq IA, Williams J, Farrell GC. NADPH oxidase is not an essential mediator of oxidative stress or liver injury in murine MCD diet-induced steatohepatitis. J Hepatol. 2007;46:304\u201313.","journal-title":"J Hepatol"},{"issue":"5","key":"191_CR30","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1096\/fj.201700590R","volume":"32","author":"S Kumei","year":"2018","unstructured":"Kumei S, Yuhki KI, Kojima F, Kashiwagi H, Imamichi Y, Okumura T, et al. Prostaglandin I2 suppresses the development of diet-induced nonalcoholic steatohepatitis in mice. FASEB J. 2018;32(5):2354\u201365. https:\/\/doi.org\/10.1096\/fj.201700590R.","journal-title":"FASEB J."},{"issue":"1","key":"191_CR31","doi-asserted-by":"publisher","first-page":"16127","DOI":"10.1038\/s41598-018-34633-y","volume":"8","author":"J Henkel","year":"2018","unstructured":"Henkel J, Coleman CD, Schraplau A, Johrens K, Weiss TS, Jonas W, et al. Augmented liver inflammation in a microsomal prostaglandin E synthase 1 (mPGES-1)-deficient diet-induced mouse NASH model. Sci Rep. 2018;8(1):16127. https:\/\/doi.org\/10.1038\/s41598-018-34633-y.","journal-title":"Sci Rep."},{"issue":"3","key":"191_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10238-014-0304-7","volume":"15","author":"MK Tsai","year":"2015","unstructured":"Tsai MK, Hsieh CC, Kuo HF, Lee MS, Huang MY, Kuo CH, et al. Effect of prostaglandin I2 analogs on monocyte chemoattractant protein-1 in human monocyte and macrophage. Clin Exp Med. 2015;15(3):245\u201353. https:\/\/doi.org\/10.1007\/s10238-014-0304-7.","journal-title":"Clin Exp Med."},{"key":"191_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fphar.2018.00553","volume":"9","author":"XY Pan","year":"2018","unstructured":"Pan XY, Yang Y, Meng HW, Li HD, Chen X, Huang HM, et al. DNA Methylation of PTGIS Enhances Hepatic Stellate Cells Activation and Liver Fibrogenesis. Front Pharmacol. 2018;9:553. https:\/\/doi.org\/10.3389\/fphar.2018.00553.","journal-title":"Front Pharmacol."},{"issue":"12","key":"191_CR34","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1172\/JCI119103","volume":"98","author":"A Mallat","year":"1996","unstructured":"Mallat A, Preaux AM, Serradeil-Le Gal C, Raufaste D, Gallois C, Brenner DA, et al. Growth inhibitory properties of endothelin-1 in activated human hepatic stellate cells: a cyclic adenosine monophosphate-mediated pathway. Inhibition of both extracellular signal-regulated kinase and c-Jun kinase and upregulation of endothelin B receptors. J Clin Invest. 1996;98(12):2771\u20138. https:\/\/doi.org\/10.1172\/JCI119103.","journal-title":"J Clin Invest."},{"issue":"9","key":"191_CR35","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s41374-021-00531-7","volume":"101","author":"XY Pan","year":"2021","unstructured":"Pan XY, Wang L, You HM, Cheng M, Yang Y, Huang C, et al. Alternative activation of macrophages by prostacyclin synthase ameliorates alcohol induced liver injury. Lab Invest. 2021;101(9):1210\u201324.","journal-title":"Lab Invest"},{"issue":"2","key":"191_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jhep.2007.03.019","volume":"47","author":"CJ Steib","year":"2007","unstructured":"Steib CJ, Gerbes AL, Bystron M, Op den Winkel M, Hartl J, Roggel F, et al. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol. 2007;47(2):228\u201338. https:\/\/doi.org\/10.1016\/j.jhep.2007.03.019.","journal-title":"J Hepatol."}],"container-title":["Inflammation and Regeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-021-00191-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41232-021-00191-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41232-021-00191-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T22:07:43Z","timestamp":1643666863000},"score":1,"resource":{"primary":{"URL":"https:\/\/inflammregen.biomedcentral.com\/articles\/10.1186\/s41232-021-00191-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["191"],"URL":"https:\/\/doi.org\/10.1186\/s41232-021-00191-6","relation":{},"ISSN":["1880-8190"],"issn-type":[{"value":"1880-8190","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,1]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in compliance with institutional regulations, and the study protocols were approved by the Institutional Animal Care and Committee of Niigata University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Y. Sakai. is the CEO of Lind Pharma, Inc. Y. Sawa and S. Miyagawa are the scientific advisers of Lind Pharma Inc. The ONO-1301 was provided by Lind Pharma Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}